Literature DB >> 20515607

Reengineered AAV vectors: old dog, new tricks.

Aravind Asokan1.   

Abstract

Adeno-associated viral (AAV) vectors have emerged in recent years as powerful tools for therapeutic gene transfer. Successes in clinical trials and the discovery of several hundreds of naturally occurring AAV isolates have triggered efforts to understand and manipulate this deceptively simple parvovirus for a myriad of gene therapy applications. Exciting breakthroughs based on directed evolution of novel tissue-specific variants from combinatorial AAV libraries have been reported. Recent approaches driven by the availability of structural information have yielded a new generation of reengineered AAV vectors.

Entities:  

Mesh:

Year:  2010        PMID: 20515607      PMCID: PMC2900186     

Source DB:  PubMed          Journal:  Discov Med        ISSN: 1539-6509            Impact factor:   2.970


  30 in total

1.  The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy.

Authors:  Qing Xie; Weishu Bu; Smita Bhatia; Joan Hare; Thayumanasamy Somasundaram; Arezki Azzi; Michael S Chapman
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-22       Impact factor: 11.205

Review 2.  Adeno-associated virus serotypes: vector toolkit for human gene therapy.

Authors:  Zhijian Wu; Aravind Asokan; R Jude Samulski
Journal:  Mol Ther       Date:  2006-07-07       Impact factor: 11.454

3.  Production, purification and preliminary X-ray crystallographic studies of adeno-associated virus serotype 1.

Authors:  Edward B Miller; Brittney Gurda-Whitaker; Lakshmanan Govindasamy; Robert McKenna; Sergei Zolotukhin; Nicholas Muzyczka; Mavis Agbandje-McKenna
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2006-11-30

4.  Structurally mapping the diverse phenotype of adeno-associated virus serotype 4.

Authors:  Lakshmanan Govindasamy; Eric Padron; Robert McKenna; Nicholas Muzyczka; Nikola Kaludov; John A Chiorini; Mavis Agbandje-McKenna
Journal:  J Virol       Date:  2006-09-13       Impact factor: 5.103

5.  Production, purification and preliminary X-ray crystallographic studies of adeno-associated virus serotype 7.

Authors:  Odayme Quesada; Brittney Gurda; Lakshmanan Govindasamy; Robert McKenna; Erik Kohlbrenner; George Aslanidi; Sergei Zolotukhin; Nicholas Muzyczka; Mavis Agbandje-McKenna
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2007-11-30

6.  Structure of adeno-associated virus serotype 8, a gene therapy vector.

Authors:  Hyun-Joo Nam; Michael Douglas Lane; Eric Padron; Brittney Gurda; Robert McKenna; Erik Kohlbrenner; George Aslanidi; Barry Byrne; Nicholas Muzyczka; Sergei Zolotukhin; Mavis Agbandje-McKenna
Journal:  J Virol       Date:  2007-08-29       Impact factor: 5.103

Review 7.  Pathophysiology of duchenne muscular dystrophy: current hypotheses.

Authors:  Nicolas Deconinck; Bernard Dan
Journal:  Pediatr Neurol       Date:  2007-01       Impact factor: 3.372

8.  Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors.

Authors:  Sylvie Boutin; Virginie Monteilhet; Philippe Veron; Christian Leborgne; Olivier Benveniste; Marie Françoise Montus; Carole Masurier
Journal:  Hum Gene Ther       Date:  2010-06       Impact factor: 5.695

9.  Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection.

Authors:  Carmela Zincarelli; Stephen Soltys; Giuseppe Rengo; Joseph E Rabinowitz
Journal:  Mol Ther       Date:  2008-04-15       Impact factor: 11.454

10.  Production, purification, crystallization and preliminary X-ray structural studies of adeno-associated virus serotype 5.

Authors:  Michael DiMattia; Lakshmanan Govindasamy; Hazel C Levy; Brittney Gurda-Whitaker; Amy Kalina; Erik Kohlbrenner; John A Chiorini; Robert McKenna; Nicholas Muzyczka; Sergei Zolotukhin; Mavis Agbandje-McKenna
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2005-09-30
View more
  8 in total

Review 1.  Percutaneous approaches for efficient cardiac gene delivery.

Authors:  Kiyotake Ishikawa; Jaume Aguero; Charbel Naim; Kenneth Fish; Roger J Hajjar
Journal:  J Cardiovasc Transl Res       Date:  2013-06-08       Impact factor: 4.132

2.  Cardiac I-1c overexpression with reengineered AAV improves cardiac function in swine ischemic heart failure.

Authors:  Kiyotake Ishikawa; Kenneth M Fish; Lisa Tilemann; Kleopatra Rapti; Jaume Aguero; Carlos G Santos-Gallego; Ahyoung Lee; Ioannis Karakikes; Chaoqin Xie; Fadi G Akar; Yuichi J Shimada; Judith K Gwathmey; Aravind Asokan; Scott McPhee; Jade Samulski; Richard Jude Samulski; Daniel C Sigg; Thomas Weber; Evangelia G Kranias; Roger J Hajjar
Journal:  Mol Ther       Date:  2014-07-15       Impact factor: 11.454

Review 3.  Adeno-associated virus delivery of broadly neutralizing antibodies.

Authors:  Bruce C Schnepp; Philip R Johnson
Journal:  Curr Opin HIV AIDS       Date:  2014-05       Impact factor: 4.283

Review 4.  Promise of adeno-associated virus as a gene therapy vector for cardiovascular diseases.

Authors:  Abesh Bera; Dwaipayan Sen
Journal:  Heart Fail Rev       Date:  2017-11       Impact factor: 4.214

5.  Intravenous Infusion of AAV for Widespread Gene Delivery to the Nervous System.

Authors:  Dominic J Gessler; Phillip W L Tai; Jia Li; Guangping Gao
Journal:  Methods Mol Biol       Date:  2019

Review 6.  Therapies for rare diseases: therapeutic modalities, progress and challenges ahead.

Authors:  Erik Tambuyzer; Benjamin Vandendriessche; Christopher P Austin; Philip J Brooks; Kristina Larsson; Katherine I Miller Needleman; James Valentine; Kay Davies; Stephen C Groft; Robert Preti; Tudor I Oprea; Marco Prunotto
Journal:  Nat Rev Drug Discov       Date:  2019-12-13       Impact factor: 84.694

7.  Use of a lower dosage liver-detargeted AAV vector to prevent hamster muscular dystrophy.

Authors:  Ida Luisa Rotundo; Alessio Lancioni; Marco Savarese; Luca D'Orsi; Michele Iacomino; Gerardo Nigro; Giulio Piluso; Alberto Auricchio; Vincenzo Nigro
Journal:  Hum Gene Ther       Date:  2013-04-04       Impact factor: 5.695

Review 8.  Emerging Vaccine Technologies.

Authors:  Rebecca J Loomis; Philip R Johnson
Journal:  Vaccines (Basel)       Date:  2015-05-26
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.